News

Under a previously announced agreement, Sciele Pharma will exclusively market PrandiMet to physicians in the US. Sciele Pharma anticipates that PrandiMet will be available to physicians and patients

The collaboration provides Genzyme with exclusive worldwide rights to mipomersen, a novel lipid-lowering drug discovered and developed by Isis that is in Phase III clinical development. During the

Trinity Biotech’s HIV-1 Bed incidence assay is a second generation assay designed to detect recent HIV seroconversion by determination of the relative proportion of HIV specific IgG to

Frontage made an initial 20% equity investment in Advanced Biomedical Research (ABR) in 2007 and acquires the remaining 80% equity with the completion of this transaction. Frontage and

According to Laboratory Corporation of America (LabCorp), in a recent study of high risk and average risk subjects, this blood test, using six biomarkers and research conducted at

Under the terms of the agreement, Orthofix will pay Intelligent Implant Systems (IIS) up to $7 million for the assignment of the intellectual property and other performance milestones,

The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort as the steroid comparator arm. The study is expected to be completed by the end of third quarter 2008.

This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent, the company said. Oral and gastrointestinal mucositis is a

This three-month extension allows the FDA time to complete its review. The prasugrel new drug application was granted priority review by the FDA in February 2008. The new